These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29684141)

  • 1. Insights about minority HIV-1 strains in transmitted drug resistance mutation dynamics and disease progression.
    Leda AR; Hunter J; Oliveira UC; Azevedo IJ; Sucupira MCA; Diaz RS
    J Antimicrob Chemother; 2018 Jul; 73(7):1930-1934. PubMed ID: 29684141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive Drug-resistant Mutation Profiles and Interpretations of HIV-1 Proviral DNA Revealed by Deep Sequencing in Reverse Transcriptase.
    Yin QQ; Li ZP; Zhao H; Pan D; Wang Y; Xu WS; Xing H; Feng Y; Jiang SB; Shao YM; Ma LY
    Biomed Environ Sci; 2016 Apr; 29(4):239-47. PubMed ID: 27241734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of pretreatment minority HIV-1 reverse transcriptase inhibitor-resistant variants by ultra-deep sequencing has a limited impact on virological outcomes.
    Su B; Zheng X; Liu Y; Liu L; Xin R; Lu H; Huang C; Bai L; Mammano F; Zhang T; Wu H; Sun L; Dai L
    J Antimicrob Chemother; 2019 May; 74(5):1408-1416. PubMed ID: 30668734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
    Couto-Fernandez JC; Silva-de-Jesus C; Veloso VG; Rachid M; Gracie RS; Chequer-Fernandez SL; Oliveira SM; Arakaki-Sanchez D; Chequer PJ; Morgado MG
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):73-8. PubMed ID: 15867968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1C proviral DNA for detection of drug resistance mutations.
    Huruy K; Mulu A; Liebert UG; Maier M
    PLoS One; 2018; 13(10):e0205119. PubMed ID: 30286160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Niubó J; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2012; 17(3):577-83. PubMed ID: 22301439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 proviral resistance mutations: usefulness in clinical practice.
    Kabamba-Mukadi B; Duquenne A; Henrivaux P; Musuamba F; Ruelle J; Yombi JC; Bodéus M; Vandercam B; Goubau P
    HIV Med; 2010 Sep; 11(8):483-92. PubMed ID: 20163482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
    Silver N; Paynter M; McAllister G; Atchley M; Sayir C; Short J; Winner D; Alouani DJ; Sharkey FH; Bergefall K; Templeton K; Carrington D; Quiñones-Mateu ME
    AIDS Res Ther; 2018 Nov; 15(1):18. PubMed ID: 30409215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
    Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
    AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations.
    Pingen M; van der Ende ME; Wensing AM; el Barzouhi A; Simen BB; Schutten M; Boucher CA
    HIV Med; 2013 Mar; 14(3):176-81. PubMed ID: 22989004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil.
    Cavalcanti AM; Lacerda HR; Brito AM; Pereira S; Medeiros D; Oliveira S
    Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):785-92. PubMed ID: 17992369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia.
    Rodriguez C; Nere ML; Demontant V; Charreau I; Mercier-Darty M; Delagreverie H; Salmona M; de Castro N; Chaix ML; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2018 Nov; 73(11):3122-3128. PubMed ID: 30137335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men.
    Chaillon A; Nakazawa M; Wertheim JO; Little SJ; Smith DM; Mehta SR; Gianella S
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Aspects of the Virus Life Cycle and Clinical Utility of Next Generation Sequencing based HIV-1 Resistance Testing in the Genomic, the Proviral, and the Viral Reservoir of Peripheral Blood Mononuclear Cells.
    Pröll J; Paar C; Taylor N; Skocic M; Freystetter A; Blaimschein A; Mayr R; Niklas N; Atzmüller S; Raml E; Wechselberger C
    Curr HIV Res; 2022; 20(3):213-221. PubMed ID: 35331114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.